This summary outlines a critical event for MANGOCEUTICALS, INC. (MGRX), as detailed in its recent SEC filing.

---

MANGOCEUTICALS, INC. Material Event - Verified Summary

Event Description (what happened)

MANGOCEUTICALS, INC. (ticker: MGRX) recently received a warning letter from Nasdaq, signaling a serious risk to its stock exchange listing. The company's stock price has consistently traded below the required minimum of $1.00 per share, violating Nasdaq Listing Rule 5550(a)(2). This rule mandates that listed companies maintain a minimum closing bid price of $1.00 per share. Mangoceuticals' stock closed below this $1.00 threshold for 30 consecutive business days, triggering the warning and risking delisting from the Nasdaq stock exchange.

Event Date/Timeline

Mangoceuticals received the official Nasdaq notice on February 4, 2026, and publicly filed this information in an 8-K on February 6, 2026. The company now has 180 calendar days, until August 3, 2026, to regain compliance. During this period, its stock will continue to trade on Nasdaq as usual. To satisfy the requirement, Mangoceuticals' stock price must close at $1.00 per share or more for at least 10 consecutive business days within this 180-day timeframe.

Impact Assessment (who/what is affected)

If Mangoceuticals fails to meet the minimum bid price requirement, Nasdaq could delist its stock. Delisting would move the stock to a less prestigious exchange, such as the OTC Markets. This typically makes it harder for investors to trade shares, reduces the company's visibility, and could damage its reputation and future ability to raise capital. While this notice does not immediately affect trading, it serves as a serious warning that the company must address not only its stock price but also the underlying issues contributing to its decline.

Who is affected:

• Investors: Delisting often leads to reduced liquidity, making shares harder to buy or sell quickly, and typically results in a lower stock price. The uncertainty surrounding this situation can also cause significant stock price fluctuations.
• Employees: While not immediately impacted, the company's financial health and future prospects could indirectly affect them. This is especially true if the company struggles to raise capital, maintain its market presence, or if underlying business issues persist.
• Customers: This event is unlikely to directly affect customers. However, a struggling company might eventually impact product development or service quality.
• Competitors: Competitors will monitor the situation closely. A company facing delisting concerns may appear weaker, potentially giving rivals an advantage.

Financial Impact (if applicable)

The 8-K filing does not quantify a direct, immediate financial impact. However, the notice highlights significant potential financial implications:

• Market Value and Capital Raising: The consistently low stock price, which triggered this warning, often signals underlying concerns about the company's financial performance, operational challenges, or investor confidence. If delisted, the company could find it harder to raise capital in the future and significantly impact its market valuation.
• Liquidity and Shareholder Value: Delisting can reduce stock liquidity, making it harder for investors to buy or sell shares quickly, and often results in a lower stock price. The uncertainty surrounding delisting risk can also cause significant stock price volatility.
• Operational Impact: While the 8-K doesn't directly state this, a struggling company facing delisting concerns may experience indirect impacts on its financial health and future prospects. This could affect its ability to fund operations, product development, or maintain market presence.
• Further Information: The 8-K filing doesn't detail why Mangoceuticals' stock has traded so low. Investors should review the company's recent quarterly (10-Q) and annual (10-K) financial reports to assess trends in revenue, profitability, cash flow, and any specific business challenges MGRX faces. This will provide a fuller financial context.

Key Takeaways for Investors

• Keep an eye on the stock price: Expect significant volatility in the short term as the market processes this news and as the deadline approaches.
• Watch the $1.00 mark: This is the critical threshold. Pay close attention to whether the stock can consistently trade above $1.00 for 10 consecutive days.
• Look for a concrete strategy: The 8-K lacks Mangoceuticals' specific plan to regain compliance. The company must communicate a clear strategy, which could involve operational improvements, new product launches, cost reductions, or a reverse stock split. Investors should watch for future announcements or investor calls. The company mentioned it will "actively monitor" its stock price and "consider available options," but honestly, the filing doesn't give us much detail on their actual strategy yet.
• Understand the underlying issues: Don't just focus on the delisting risk. Research the company's recent financial performance (10-K, 10-Q filings) to understand why the stock price has fallen. Is it a temporary setback or a sign of deeper, systemic problems?
• Understand the risk: While not an immediate delisting, this is a serious risk. Delisting can significantly impact the value and tradability of your shares.
• Do your own homework: This summary provides a quick overview. Always conduct your own thorough research before making significant investment decisions, especially with a company facing a listing deficiency and vague strategic plans.